A Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Study of DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2018
At a glance
- Drugs DSP 6952 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 05 Jun 2018 Status changed from active, no longer recruiting to completed.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Dec 2016 New trial record